Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDUA | P35475 | 4/20 | 0.69 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.33 |
| ▸ | IGF2R | P11717 | 1/20 | 0.33 |
| ▸ | FGF2 | P09038 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | LRAT | O95237 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19784383 | 1.00 | IDUA (0.69) | IDUASUCNR1LGALS3IGF2RFGF2 | |
| SCHEMBL18820172 | 1.00 | IDUA (0.69) | IDUASUCNR1LGALS3IGF2RFGF2 | |
| SCHEMBL18820169 | 1.00 | IDUA (0.69) | IDUASUCNR1LGALS3IGF2RFGF2 | |
| SCHEMBL18820170 | 1.00 | IDUA (0.69) | IDUASUCNR1LGALS3IGF2RFGF2 | |
| SCHEMBL18830622 | 1.00 | IDUA (0.69) | IDUASUCNR1LGALS3IGF2RFGF2 | |
| SCHEMBL18830487 | 1.00 | IDUA (0.69) | IDUASUCNR1LGALS3IGF2RFGF2 | |
| SCHEMBL19784458 | 1.00 | IDUA (0.69) | IDUASUCNR1LGALS3IGF2RFGF2 | |
| SCHEMBL18830623 | 1.00 | IDUA (0.69) | IDUASUCNR1LGALS3IGF2RFGF2 | |
| SCHEMBL20888700 | 1.00 | IDUA (0.69) | IDUASUCNR1LGALS3IGF2RFGF2 | |
| SCHEMBL18820166 | 1.00 | IDUA (0.69) | IDUASUCNR1LGALS3IGF2RFGF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170119902-A1 | ANTIBODY-DRUG CONJUGATE (ADC) AND METHOD FOR FORMING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119902-A1 | ANTIBODY-DRUG CONJUGATE (ADC) AND METHOD FOR FORMING THE SAME | DNPEP, DLST, DDOST | IDUA 9/4885SUCNR1 2788/4885LGALS3 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.